Can Finerenone Be Used in Dilated Cardiomyopathy with EF 30%?
Yes, finerenone can be prescribed for dilated cardiomyopathy with an ejection fraction of 30%, as this falls within the heart failure with reduced ejection fraction (HFrEF) category where finerenone has demonstrated cardiovascular benefit, though it currently awaits formal FDA approval and guideline incorporation for this specific indication.
Current Evidence Status
The most recent and highest-quality evidence comes from the FINEARTS-HF trial 1, which demonstrated that finerenone reduced the primary outcome of cardiovascular death or total heart failure hospitalizations by 15% in patients with heart failure, driven primarily by a 17% reduction in total heart failure hospitalizations. However, this trial focused on heart failure with mildly reduced or preserved ejection fraction (LVEF ≥40%), not specifically on HFrEF with EF 30% 1.
Critical limitation: The 2023-2025 diabetes and CKD guidelines explicitly state that patients with heart failure with reduced ejection fraction were excluded from the FIDELIO-DKD and FIGARO-DKD trials 2. This creates an evidence gap for your specific patient population.
Clinical Decision Algorithm
Step 1: Assess Comorbidities
- If patient has type 2 diabetes AND chronic kidney disease: Finerenone has strongest evidence here 3, 2
- FIDELIO-DKD and FIGARO-DKD showed 13-14% reduction in cardiovascular outcomes
- Benefits included reduced heart failure hospitalizations even in diabetic CKD patients
- Pooled FIDELITY analysis confirmed benefits across CKD spectrum 3
Step 2: Check Eligibility Criteria
Before prescribing, verify:
- Potassium ≤4.8 mmol/L (mandatory) 3, 4
- eGFR ≥25 mL/min/1.73 m² 5
- No severe uncontrolled hypertension 2
- Patient not already on high-dose steroidal MRA (spironolactone/eplerenone)
Step 3: Dosing Strategy
- eGFR 25-60 mL/min/1.73 m²: Start 10 mg once daily 3, 4
- eGFR ≥60 mL/min/1.73 m²: Start 20 mg once daily 3, 4
- Uptitrate to 20 mg after 1 month if potassium ≤4.8 mmol/L and eGFR stable 4
Step 4: Prioritize Guideline-Directed Medical Therapy (GDMT)
Before adding finerenone, ensure optimization of:
- ACE inhibitor or ARB (Class I, Level A) 6
- Beta-blocker proven in HFrEF trials (Class I, Level A) 6
- SGLT2 inhibitor (empagliflozin or dapagliflozin) - prioritize this first 7, 8
- Consider spironolactone if LVEF <30% and severe symptoms (Class I, Level B) 6
Important caveat: The 2006 Canadian guidelines explicitly discourage combining ACE inhibitor, ARB, and aldosterone antagonist together unless followed closely in a specialist heart failure clinic due to hyperkalemia risk 6. This same concern applies to finerenone.
Safety Monitoring Protocol
Baseline Assessment
- Serum potassium
- eGFR/creatinine
- Blood pressure (supine and standing)
Follow-up Monitoring
- Recheck potassium and eGFR at 4 weeks after initiation or dose change 4, 9
- Reassess during any acute illness or unstable renal function 9
- In FIGARO-DKD: 10.8% developed hyperkalemia vs 5.3% placebo, but only 1.2% discontinued 4
- Expect acute eGFR dip of ≥10% in approximately 31% of patients (vs 19% placebo) 10
Practical Implementation Considerations
Finerenone offers advantages over steroidal MRAs:
- More selective for mineralocorticoid receptor 11, 12
- Lower risk of antiandrogenic side effects 12
- Equal distribution between heart and kidneys 13
- Lower hyperkalemia rates compared to spironolactone 12
However, recognize these limitations:
- FDA approval currently pending for heart failure indication 1
- Not yet incorporated into heart failure guidelines 1
- Most robust evidence exists for diabetic CKD patients, not pure HFrEF 3, 2
- Excluded patients with HFrEF from pivotal diabetic CKD trials 2
Combination Therapy Strategy
Optimal sequence for your patient:
- First: Ensure SGLT2 inhibitor on board - reduces hyperkalemia risk when combined with MRA 8
- Second: Consider finerenone if patient has diabetes + CKD (strongest evidence) 3, 7
- Alternative: Use steroidal MRA (spironolactone) if LVEF <30% with severe symptoms - this has Class I, Level B recommendation 6
The 2025 guideline notes that SGLT2 inhibitors reduce serious hyperkalemia risk (HR 0.84) when combined with RAAS inhibitors and MRAs 8, making this combination safer than historical concerns suggested.
Bottom Line
For dilated cardiomyopathy with EF 30%: Finerenone is physiologically rational and likely beneficial based on mechanism of action and emerging evidence 11, 14, but formal approval and guidelines are pending 1. If your patient has concurrent type 2 diabetes and CKD, prescribe finerenone with confidence based on FIDELIO-DKD/FIGARO-DKD data showing cardiovascular benefits including reduced heart failure hospitalizations 3, 4, 2. If no diabetes/CKD, consider traditional spironolactone first (Class I recommendation for LVEF <30%) 6 while awaiting formal finerenone approval for HFrEF. Always ensure SGLT2 inhibitor is prescribed first to mitigate hyperkalemia risk 8.